FDA Begins Safety Review of Bleeding With BI’s Pradaxa

Washington Drug Letter
The FDA is reviewing postmarket reports of serious bleeding events in patients taking Boehringer Ingelheim’s blood-thinner Pradaxa just as the drug is facing increased competition with approval of Johnson & Johnson and Bayer’s Xarelto in atrial fibrillation (AF) patients.

To View This Article:


Buy This Article Now

Add this article to your cart for $25.00